Cost-Effectiveness Of Bendamustine+Rituximab Versus Fludarabine+Rituximab In The Treatment Of Relapsed Indolent Non-Hodgkin's And Mantle Cell Lymphomas In Canada

The Cost-Effectiveness of Bendamustine-R

The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico

✍ Bertwistle, D.; Munakata, J.; Wehler, E.; Leyva, V.; Valencia, A.; Hernandez, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

The Cost-Effectiveness of Bendamustine-R

The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Colombia

✍ Bertwistle, D.; Munakata, J.; Wehler, E; Leyva, V.; Ariza, J.G.; Zambrano, C.; G 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB

Phase I trial of fludarabine, bortezomib

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

✍ Paul M. Barr; Pingfu Fu; Hillard M. Lazarus; Nancy Horvath; Stanton L. Gerson; O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

An evaluation of the potential for drug–

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma

✍ Darwish, Mona; Burke, John M.; Hellriegel, Edward; Robertson, Philmore; Phillips 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 424 KB

Bendamustine for the treatment of chroni

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma

✍ Trevor W. Dennie; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 209 KB